On 28 April 2026, Celltrion announced the launch of Avtozma®/CT-P47, biosimilar to Roche’s Actemra® (tocilizumab), in Japan. Avtozma® is the first tocilizumab biosimilar to be launched in Japan, having also been the first to receive approval in September 2025.
Avtozma® is approved for all reference indications and will be sold in Japan by Celltrion’s Japanese subsidiary. Avtozma® has also received marketing authorisation in a number of other regions, including the US (January 2025), and was the first tocilizumab biosimilar approved in Australia (May 2025) and New Zealand (December 2025).
There is at least one other tocilizumab biosimilar approved in Japan, with Gedeon Richter/Mochida Pharmaceutical/Ayumi Pharmaceutical’s RGB-19 (marketed as Tuyory® in the EU) approved in March 2026 in IV, SC and autoinjector formulations.